history of glp 1 agonists Another milestone in the evolution GLP-1-based diabetes therapies The expanding landscape of GLP-1

[DOI] [PubMed] [Google Scholar] 14.Drucker DJ, Habener JF, Holst JJ

Pooled mean follow-up on-treatment for semaglutide users was 193 days (median 157 days, interquartile range (IQR) 85 to 331 days) and for sitagliptin users 195 days (median 160 days, IQR 95 to 322 days)

Although diabetic patients and individuals with vascular disease face a higher baseline risk, anyone experiencing sudden changes in vision should seek immediate medical attention to protect their eye health and identify potential underlying conditions affecting the body

Decreasing waist circumference with stable or increasing limb measurements suggests favorable fat loss with lean mass preservation

2024;326(3):E26876